

| | | |
|--|---------------------------------|---------------------------------|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: 184.5-US-WO | Int'l Appln No: PCT/GB03/003801 |
| | Applicant: Alan Crossman et al. | |
| | Filing Date: March 20, 2009 | Group Art Unit: 3221 |

| U.S. PATENT DOCUMENTS | | | | | | |
|---|--------------|---|------------------|-------|----------|----------------------------|
| EXAMINER INITIAL | DOCUMENT NO. | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | 4,322,346 | 03/1982 | Korosi et al. | | | |
| | 4,452,808 | 06/1984 | Gallagher, Jr. | | | |
| | 4,513,006 | 04/1985 | Maryanoff et al. | | | |
| | 4,582,916 | 04/1986 | Maryanoff et al. | | | |
| | 4,824,860 | 04/1989 | Owen | | | |
| | 6,200,970 | 03/2001 | Ling et al. | | | |
| | 6,420,369 | 07/2002 | Marcotte | | | |
| | 6,559,293 | 05/2003 | Almarsson et al. | | | |
| | 6,583,172 | 06/2003 | Shank | | | |
| | 6,649,607 | 11/2003 | Leventer et al. | | | |
| FOREIGN PATENTS | | | | | | |
| | DOCUMENT NO. | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION |
| | | | | | | YES NO |
| | 0138441 | 08/1988 | EP | | | |
| | 0900568 | 03/1999 | EP | | | |
| | 99/06408 | 02/1999 | WO | | | |
| | 01/04122 | 01/2001 | WO | | | |
| | 02/088096 | 11/2002 | WO | | | |
| | 02/094189 | 11/2002 | WO | | | |
| NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | |
| | | Beers et al., "The Merck Manual of Diagnosis and Therapy, 17th Edition", 1999, Merck Research Laboratories Whitehouse Station, NJ, pp. 1462-1473, XP002267011. | | | | |
| | | Beloborodova et al., "Method of Treatment of Hypertension-Hyperkinetic form of Dyskinesia of Biliferous Ways in Young Persons", 12/27/02, Abstract, XP002266976. | | | | |
| | | Blanchet et al., "Differing Effects of N-Methyl-D-Aspartate Receptor Subtype Selective Antagonists on Dyskinesias in Levodopa-Treated 1-Methyl-4-Phenyl-Tetrahydropyridine Monkeys," JPET, vol. 290, no. 3, 1999, pp. 1034-1040. | | | | |
| | | Brochie et al., "The Effects of Tolisopam on the Actions Induced by L-DOPA Administration in the MPTP - Lesioned Non-Human Primate Model of Parkinson's Disease", Society for Neuroscience Abstract Viewer and Itinerary Planner, 2002, Program No. 165.18, pp. 1-2, XP008026196. | | | | |
| | | Burne et al., "The Contribution of Tremor Studies to Diagnosis of Parkinsonian and Essential Tremor: A Statistical Evaluation," Journal of Clinical Neuroscience, vol. 9, no. 3, 2002, pp. 237-242. | | | | |
| | | Connor, "A Double-Blind Placebo-Controlled Trial of Topiramate Treatment for Essential Tremor," Neurology, 59, 2002, pp. 132-134. | | | | |
| | | Fox et al., "Neural Mechanisms Underlying Peak-Dose Dyskinesia Induced by Levodopa and Apomorphine are Distinct: Evidence from the Effects of the Alpha2 Adrenoceptor Antagonist Idazoxan," Movement Disorders, vol. 16, no. 4, 2001, pp. 642-650. | | | | |
| EXAMINER: | | | DATE CONSIDERED: | | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | | | | | | |

*Substitute Disclosure Statement Form (PTO 1449)

| | | |
|--|---------------------------------|---|
| Form 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION | Docket Number: 184.5-US-WO | Int'l Appl. No.: PCT/GB03/003801 Int'l Filing Date: 01 Sept 2003 |
| | Applicant: Alan Crossman et al. | |
| | Filing Date: March 20, 2009 | Group Art Unit: 3221 |

| | |
|--|--|
| | Henry et al., "μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's Disease," <i>Experimental Neurology</i> , 171, 2001, pp. 139-146. |
| | Kanda et al., "Combined Use of the Adenosine A _{2A} Antagonist KW-6002 with L-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity by Not Dyskinesia in MPTP-Treated Monkeys," <i>Experimental Neurology</i> , 162, 2000, pp. 321-327. |
| | Konitsiotis et al., "AMPA Receptor Blockade Improves Levodopa-Induced Dyskinesia in MPTO Monkeys," <i>Neurology</i> , Vol. 54, No. 8, April 25, 2000, pp. 1589-1595, XP008026187. |
| | Levine, "Medical Treatment of Essential Tremor and Parkinson's Disease," <i>Geriatrics</i> , vol. 53, issue 5, May 1998, 10 pages. |
| | Nash et al., "Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease," <i>Experimental Neurology</i> , 165, 2000, pp. 136-142. |
| | Revutsky et al., "Prophylaxis of Metapathological Reactions in Patients with Ischemic heart Disease and Neurocirculatory Dystonia", <i>Vrachebnoe Delo</i> 1988 Russia, No. 2, 1988, pp. 7-10, XP008026189. |
| | Skradski et al., "Topiramate Blocks Kainate-Evoke Cobolt Influx into Cultured Neurons," <i>Epilepsia</i> , 41 (Suppl. 1), 2000, pp. S45-S47. |
| | Solyom et al., "Non-Competitive AMPA Antagonists of 2,3-Benzodiazepin Type", <i>Current Pharmaceutical Design</i> 2002, Netherlands, Vol. 8, No. 10, 2002, pp. 913-939, XP008026188. |
| | Tarnawa et al., "2,3-Benzodiazepine AMPA Antagonists", <i>Restorative Neurology and Neuroscience</i> , 1998, Vol. 13, pp. 41-57, XP008026184. |
| | Wolters et al., "Parkinson's Disease," <i>Recent Advances in Pharmacotherapy, CMAJ</i> , vol. 140, March 1, 1989, pp. 507-513. |
| | Answers.com, dyskinesia, http://www.answers.com/topic/dyskinesia , printed 09/11/2008, 4 pages. |

| | |
|---|------------------|
| EXAMINER: | DATE CONSIDERED: |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant. | |